Symbiotec secures 10-year EU alternative-protein CDMO agreement

Symbiotec Pharmalab Limited on November 6, 2026 announced a 10-year take-or-pay contract development and manufacturing agreement to produce fermentation-based alternative protein for a European innovator, with dedicated capacity reserved at its Ujjain campus for the full term. The company did not disclose the agreement’s consideration because of confidentiality obligations.

What did Symbiotec announce on November 6, 2026?

Symbiotec announced a 10-year international contract development and manufacturing organisation, or CDMO, agreement with a leading European alternative-protein innovator on November 6, 2026. The agreement covers fermentation-based alternative protein and reserves dedicated manufacturing capacity at the Ujjain campus for the partner during the stated term.

The counterparty is identified only as a leading European alternative-protein innovator in the November 2026 filing. Symbiotec did not disclose its name, the intended end market for the protein, or the countries where the partner expects to sell products containing the fermentation-derived ingredient.

The filing describes the arrangement as strategic CDMO manufacturing, rather than as a one-time supply order. Symbiotec’s disclosed purpose is to manufacture fermentation-based alternative protein for the European innovator, while the company’s wider business profile identifies three verticals: active pharmaceutical ingredients, CDMO services and complex injectables.

Precision fermentation is the mechanism identified for the programme. Symbiotec says it uses engineered microorganisms to make proteins traditionally derived from animals, and describes the resulting product as an ingredient requiring both high quality standards and production economics that can support wider adoption.

What does the 10-year take-or-pay agreement establish?

The 10-year take-or-pay agreement establishes that dedicated Ujjain capacity is reserved for the European partner for the full contract term. Symbiotec characterises the November 2026 arrangement as a CDMO agreement, with production to be based at its biomanufacturing campus in Ujjain.

The filing does not state a minimum purchase quantity, annual manufacturing schedule, product price, payment timetable or a take-or-pay threshold. Therefore, the disclosed 10-year duration and capacity reservation cannot be translated into annual revenue, order backlog or a quantified payment commitment from the information provided.

Annexure A classifies the agreement as international. The same disclosure records “NA” for whether the European counterparty is related to Symbiotec’s promoter, promoter group or group companies, and “NA” for whether the transaction falls within related-party transactions.

The Ujjain commitment is specific to this programme, whereas Symbiotec says its overall manufacturing network comprises four facilities in Madhya Pradesh. The source does not state whether the reserved alternative-protein capacity will be newly allocated, drawn from currently available capacity, or affect output for another product category.

What Ujjain capacity will produce the alternative protein?

Symbiotec will start alternative-protein production at its existing Ujjain facility, which has four 100-kilolitre fermenters. Those four vessels equal 400 kilolitres of stated fermenter capacity, alongside modular downstream processing and integrated quality assurance and quality control capabilities.

The four 100-kilolitre fermenters are the only precise vessel specification provided for the initial production site. Symbiotec has not disclosed how much of the 400-kilolitre stated capacity will be assigned to the 10-year programme, the expected number of production batches, or output in litres or kilograms.

The source links the alternative-protein programme to Symbiotec’s pharmaceutical manufacturing systems and experience in building and operating fermentation plants. Symbiotec says it serves more than 200 customers in over 40 countries, but it does not provide a customer count, production volume or revenue associated with this European agreement.

Symbiotec’s company profile also cites approvals from the US Food and Drug Administration, European Union Good Manufacturing Practice, World Health Organization Good Manufacturing Practice and Japan’s Pharmaceuticals and Medical Devices Agency. The November 2026 announcement does not state whether any particular approval is required before the European innovator’s fermentation-based protein is sold in a given market.

How will Symbiotec expand the programme and what is undisclosed?

Symbiotec says production will begin at the existing Ujjain facility before a new dedicated plant with several hundred thousand litres of fermentation capacity follows. The company has not given a commissioning date, capital-expenditure amount, precise capacity figure or construction timetable for that future plant.

The agreement also reserves contracted expansion options for the European partner that could take the programme into millions of litres of fermentation capacity. This creates a disclosed sequence from four 100-kilolitre fermenters at the initial facility to a dedicated plant and potential larger-scale capacity, but the filing does not say if or when those options will be used.

The difference between the current Ujjain equipment and the planned facility is clear in the source. Initial production uses four fermenters with 400 kilolitres of stated capacity, while the follow-on plant is described only as having several hundred thousand litres and the optional programme scale as millions of litres.

Symbiotec disclosed no consideration, revenue estimate, margin, capital expenditure or annual minimum volume for the 10-year agreement. Annexure A says consideration details cannot be disclosed because of confidentiality obligations, so the financial value of the capacity reservation remains unspecified.

The filing also does not disclose termination conditions, exclusivity provisions, intellectual-property arrangements, pricing revisions or penalties. Management said the fermentation-derived protein marks a milestone in creating alternatives for consumers and that Symbiotec is positioned to serve alternative protein, human nutrition and industrial bioproducts; these are management statements, not financial guidance.

Conclusion

Symbiotec’s November 6, 2026 disclosure establishes a 10-year take-or-pay CDMO relationship for fermentation-based alternative protein, with dedicated Ujjain capacity reserved for an unnamed European innovator. The initial operating base is four 100-kilolitre fermenters, totalling 400 kilolitres of stated vessel capacity, but neither contract value nor committed production volume has been made public.

The next disclosed items to watch are the start of production at the existing Ujjain facility, progress on the dedicated plant described as having several hundred thousand litres of fermentation capacity, and any use of options that could extend the programme into millions of litres. Symbiotec has not disclosed dates, spending requirements, precise plant capacity or a revenue range for those planned steps.